Brief: Tetra Biopharma Survey Validates Primary Endpoint Of Serenity Clinical Trial
26/03/2020 11:18
March 26 (Reuters) - Tetra Bio Pharma Inc TBP.V :
* TETRA BIOPHARMA SURVEY VALIDATES PRIMARY ENDPOINT OF
SERENITY©
CLINICAL TRIAL
* TETRA BIO PHARMA INC - RESULTS CONFIRM THAT THE PRIMARY
ENDPOINT
IN THE SERENITY CLINICAL TRIAL IS ACCURATE
Source text for Eikon: ID:nGNX8FvX7Z
Further company coverage: TBP.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tetra Bio Pharma
See all newsBrief: Tetra Bio Receives A Second Clarifax From Health Canada Regarding Reduvo Risk Management Plan
Brief: Tetra Bio-Pharma Announces Results Of Artificial Intelligence Study Of ARDS-003 Combined With Favipiravir
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra And Prepaire Jointly Apply To Barda For Funding